QuidelOrtho Corp
QDELQuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration (FDA) issued to Quidel the first emergency use authorization (EUA) for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
26dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How QDEL's past catalysts played out
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is QuidelOrtho Corp's next FDA catalyst?→
QuidelOrtho Corp's (QDEL) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track QDEL biotech catalysts?→
Add QDEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow QuidelOrtho Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.